• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Artificial insemination Market Trends

    ID: MRFR/MED/0711-CR
    90 Pages
    Rahul Gotadki
    February 2021

    Artificial Insemination Market Size, Growth Research Report By Type (Intrauterine, Intracervical and Intratubal), End User (Hospitals & Clinics, Fertility Centre and Home-Based) and Region (Americas, Europe, Asia-Pacific and Rest of the World) - Competitor Industry Analysis and Trends Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Artificial insemination Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License

    Market Trends

    Key Emerging Trends in the Artificial insemination Market

    The Artificial Insemination market has witnessed significant growth in recent years, driven by advancements in reproductive technologies and a growing demand for efficient and controlled breeding in various animal species, including humans. Artificial insemination service from all over the world. The current market trend shows widespread adoption in many areas. Informing this expansion is the growing realization of the advantages positives that can be derived from AI in increasing fertility rates, ensuring genetic diversity, and consequently enhancing reproductive success as a whole. This vital trend that dictates the AI market is the constant development of the technological sphere. The newly emerging state-of-the-art innovations that are changing the way in which artificial insemination is undertaken include very accurate and effective AI methods that are driven by AI and also fusion of genetic screening tools. The demand for the AI services in the market livestock and agricultural is rising. An increasing number of farmers and breeders have been resorting to AI in order to establish effective breeding programs which are characterized by enhanced genetics, reduced disease vulnerability as well as increased productivity levels in both livestock and crops. In the area of reproduction, the human sphere in particular, AI is now the central figure. More couples are adopting artificial insemination as an acceptable solution in dealing with infertility issues due to increasing acceptance of AI approaches in the market. Transciention of found gender glass ceiling varies gender across the globe, due to this found effort in shadows of its National culture. Every marker trend is inclined towards low-cost alternatives in artificial insemination methods. It also encompasses the adoption of frozen semen, which improves the convenience of storage, transportation and widespread reach, thus the general accessibility of AI services. It is though the regulatory scene is changing to suit the rising numbers of artificial insemination within the society. Governments and regulatory bodies understand the need for regulations and frameworks to govern the usage of animal as well as human reproductive technology. The market is reporting a rapid increase in investments from both the public and private sectors which has been catalyzing research and developments in artificial insemination technologies. The trend towards partnership between research institutions, biotechnology companies as well as agricultural units is propping up the evolution of pioneering AI solutions. Although positive trends are evident, challenges are present which include ethical issues, need for holistic data governance policies, and knowledge of the need to address the public’s lack of confidence. A greater demand to reduce the environmental consequences of conventional reproduction methods gives rise to the use of AI as an alternative. The AI technology helps to minimise the need for large-scale breeding facilities operating with reduced impact on the ecological footprint making it market compliant to global initiatives. Market trends emphasize consumer education. After understanding the advantages and security of artificial insemination, the market is expected to garners substantial acceptance and demand in livestock farming as well as men and women with the fertility disorders. Looking ahead, the artificial insemination market is poised for continued growth. As technology continues to advance, regulatory frameworks mature, and public perception evolves, artificial insemination is expected to become an integral part of modern reproductive practices across various industries.

    Market Summary

    The Global Artificial Insemination Market is projected to grow from 4.3 USD Billion in 2024 to 11.9 USD Billion by 2032.

    Key Market Trends & Highlights

    Global Artificial Insemination Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 9.68 percent from 2025 to 2032.
    • By 2035, the market valuation is anticipated to reach 11.9 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 4.3 USD Billion, reflecting the increasing demand for artificial insemination services.
    • Growing adoption of advanced reproductive technologies due to rising infertility rates is a major market driver.

    Market Size & Forecast

    2024 Market Size 4.3 (USD Billion)
    2035 Market Size 11.9 (USD Billion)
    CAGR (2025-2035) 9.68%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Vitrolife AB, Genea Limited, Rinovum Women's Health, Pride Angel, Hi-tech Solutions, Kitazato Corporation, Fujifilm Irvine Scientific, Rocket Medical

    Market Trends

    Rising infertility rates and increased awareness among individuals about alternative reproductive treatments are two major factors influencing the market. Furthermore, governments in many countries have legalized same-sex marriage and provided insurance coverage to civil unions for artificial insemination procedures, fueling the market growth. Aside from that, the growing  population and increasing demand for animal-based protein drive the demand for artificial insemination in domestic livestock animals. Improving veterinary services and rising

    animal healthcare

    expenditure drive market growth. Furthermore, the leading players are forming strategic alliances to expand their portfolio of animal genetics and strengthen their position in various markets.

    The Global Artificial Insemination Market appears to be experiencing a notable expansion, driven by advancements in reproductive technologies and increasing awareness of fertility solutions among consumers.

    U.S. Department of Agriculture

    Artificial insemination Market Market Drivers

    Increasing Demand for Livestock Production

    The Global Artificial Insemination Market Industry experiences a notable surge in demand due to the increasing need for livestock production. As global populations rise, the demand for meat and dairy products escalates, prompting farmers to enhance productivity. Artificial insemination allows for the rapid genetic improvement of livestock, leading to healthier and more productive animals. This method is particularly advantageous in regions where traditional breeding practices are insufficient. By 2024, the market is projected to reach 4.3 USD Billion, reflecting the growing reliance on advanced reproductive technologies to meet food security challenges.

    Market Segment Insights

    Artificial Insemination Type Insights

    The market segments of artificial insemination, based on type, is intrauterine, intracervical, and intratubal. The intrauterine segment is expected exhibit a rapid CAGR and hold the largest market share in the artificial insemination market growth in 2021. This insemination method is the most used to treat infertility because it produces the highest pregnancy rate. It is also a non-invasive procedure. During the washing process, prostaglandins, pathogenic agents, antigenic proteins, nonmotile spermatozoa, immature germ cells, and other contaminants are removed, resulting in high-quality sperm.

    These are the primary benefits that will drive the intrauterine segment's growth in the  market during the forecast period. The intravaginal portion is expected to be the second largest (IVI). IVI can be performed in a fertility clinic or home, which is especially beneficial for surrogacy and donor insemination.

    Artificial Insemination

    Artificial Insemination End-User Insights

    The artificial insemination market segmentation, by type, is hospitals & clinics, fertility centers, and home-based. The fertility center segment is expected to have the largest market share in 2021 and to register the fastest CAGR during the forecast period. Fertility clinics are implementing various strategies to increase customer awareness and knowledge about available treatments and solutions for

    infertility

    problems. Because of the rise in infertility rates worldwide, several medical centers focus on providing infertility treatment. These are the major key factors driving the fertility clinics & other facilities segment's growth during the forecast period.

    Get more detailed insights about Artificial Insemination Market Research Report - Global Forecast till 2032

    Regional Insights

    Key Companies in the Artificial insemination Market market include

    Industry Developments

    • Q2 2024: CooperSurgical Launches New ARTlab™ Laboratory Management Platform for Fertility Clinics CooperSurgical announced the launch of ARTlab™, a new laboratory management platform designed to streamline workflows and improve data management in fertility clinics, supporting artificial insemination and other assisted reproductive technologies.
    • Q2 2024: Hamilton Thorne Announces Acquisition of IVFtech ApS Hamilton Thorne, a leading provider of precision instruments for fertility clinics, announced the acquisition of IVFtech ApS, a Danish manufacturer of laminar flow workstations and related products for artificial insemination and IVF laboratories.
    • Q2 2024: Fujifilm Irvine Scientific Opens New Manufacturing Facility in Tilburg, Netherlands Fujifilm Irvine Scientific opened a new manufacturing facility in the Netherlands to expand production of cell culture media used in artificial insemination and other assisted reproductive technologies, aiming to meet growing European demand.
    • Q3 2024: Vitrolife Appoints New CEO to Drive Growth in Fertility Solutions Vitrolife, a global leader in fertility treatment products including artificial insemination media, announced the appointment of a new CEO to accelerate its international expansion and product innovation.
    • Q3 2024: Cook Medical Launches Next-Generation Insemination Catheter Cook Medical introduced a next-generation insemination catheter designed to improve patient comfort and clinical outcomes in artificial insemination procedures.
    • Q4 2024: Genus plc Announces Strategic Partnership with CRV for Bovine Artificial Insemination Genus plc, a leader in animal genetics, announced a strategic partnership with CRV to jointly develop and distribute advanced bovine artificial insemination solutions in Europe.
    • Q4 2024: Pride Angel Launches Online Platform for Home Artificial Insemination Kits Pride Angel launched a new online platform offering home artificial insemination kits, aiming to increase accessibility and privacy for individuals and couples seeking fertility solutions.
    • Q1 2025: Medtronic Receives CE Mark for Automated Artificial Insemination Device Medtronic announced it has received CE Mark approval for its new automated artificial insemination device, enabling commercial launch in the European Union.
    • Q1 2025: Bayer AG Invests in Fertility Tech Startup Focused on AI-Driven Insemination Bayer AG announced a strategic investment in a fertility technology startup developing AI-driven solutions for optimizing artificial insemination outcomes.
    • Q2 2025: JLG Enterprises, Inc. Expands Manufacturing Capacity for Artificial Insemination Equipment JLG Enterprises, Inc. announced the expansion of its manufacturing facility to increase production of artificial insemination equipment, citing rising demand from fertility clinics and animal breeding centers.
    • Q2 2025: Hi-Tech Solutions Secures Series B Funding to Scale Artificial Insemination Technologies Hi-Tech Solutions, a provider of reproductive health technologies, secured Series B funding to accelerate the development and commercialization of its artificial insemination products.
    • Q2 2025: Cook Medical Receives FDA Clearance for New Artificial Insemination Syringe Cook Medical received FDA clearance for its new artificial insemination syringe, allowing for immediate commercialization in the United States.

    Artificial Insemination Market Trends

    Rising infertility rates and increased awareness among individuals about alternative reproductive treatments are two major factors influencing the market. Furthermore, governments in many countries have legalized same-sex marriage and provided insurance coverage to civil unions for artificial insemination procedures, fueling the market growth. Aside from that, the growing  population and increasing demand for animal-based protein drive the demand for artificial insemination in domestic livestock animals. Improving veterinary services and rising

    animal healthcare

    expenditure drive market growth. Furthermore, the leading players are forming strategic alliances to expand their portfolio of animal genetics and strengthen their position in various markets.

     Market Drivers

      •   Rising infertility issues in people to aid the  market growth

    Infertility is one of the most serious and widespread issues affecting today's youth worldwide. The female preference for pregnancy and the gradual increase in the number of infertile couples who require pregnancy assistance can be attributed to market growth. The age of women, the quality of their eggs, and women in their late 30s are expected to increase demand for artificial insemination. Furthermore, infertility affects over 20 million women, according to the National Women's Health Resource Center.

    Total fertility is expected to fall from 2.43 to 2.39 children per woman between 2020 and 2030, according to the 2017 United Nations World Population Prospects report. The rising prevalence of infertility among the  population drives the  market forward.

    Market Restraints:

      • Most countries have strict regulations in place regarding who is eligible to receive fertility treatments, which is stifling market growth

    Most countries' stringent regulations governing who is eligible to receive fertility treatments are impeding the growth of the  market. Italy and France, for example, prohibit lesbian couples and single women from using artificial insemination. Italy and Austria are among the countries that have banned all sperm and egg donations for IVF. Norway and Germany prohibit egg donation but permit sperm donation.

    Market Opportunities:

      • Insurance companies covering artificial insemination treatment under medical coverage

    Many insurance companies now cover artificial insemination as a medical procedure. These initiatives assist patients in fighting infertility and creating opportunities in the insurance industry. Moreover, Governments and international organizations develop policies and establish new institutions to improve medical connectivity, such as the Assisted Reproductive Technology (ART) Regulation Bill, the Nation Public Action Plan, the National Family Policy, and other initiatives. According to the UN Security Council, 84% of the country supports the policy that directly and indirectly affects the country's infertility.

    Artificial Insemination Market Segment Insights

    Artificial Insemination Type Insights

    The market segments of artificial insemination, based on type, is intrauterine, intracervical, and intratubal. The intrauterine segment is expected exhibit a rapid CAGR and hold the largest market share in the artificial insemination market growth in 2021. This insemination method is the most used to treat infertility because it produces the highest pregnancy rate. It is also a non-invasive procedure. During the washing process, prostaglandins, pathogenic agents, antigenic proteins, nonmotile spermatozoa, immature germ cells, and other contaminants are removed, resulting in high-quality sperm.

    These are the primary benefits that will drive the intrauterine segment's growth in the  market during the forecast period. The intravaginal portion is expected to be the second largest (IVI). IVI can be performed in a fertility clinic or home, which is especially beneficial for surrogacy and donor insemination.

    Artificial Insemination End-User Insights

    Future Outlook

    Artificial insemination Market Future Outlook

    The Global Artificial Insemination Market is projected to grow at a 9.68% CAGR from 2024 to 2032, driven by advancements in reproductive technologies and increasing demand for livestock productivity.

    New opportunities lie in:

    • Invest in AI-driven reproductive technologies to enhance success rates.
    • Develop specialized training programs for veterinarians in artificial insemination techniques.
    • Explore partnerships with biotech firms for innovative genetic solutions.

    By 2035, the market is expected to exhibit robust growth, reflecting evolving agricultural practices and technological advancements.

    Market Segmentation

    Artificial Insemination Type Outlook

    • Intrauterine
    • Intracervical
    • Intratubal

    Artificial Insemination End Users Outlook

    North America
    • US
    • Canada
    • Mexico

    Report Scope

    Attribute/Metric Details
    Market Size 2023 N/A (USD Billion)
    Market Size 2024 N/A (USD Billion)
    Market Size 2032 9.2 (USD Billion)
    Compound Annual Growth Rate (CAGR) 8.9 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2018-2022
    Geographies Covered  North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
    Key Vendors Vitrolife AB, Genea Limited, Rinovum Women's Health, Pride Angel, Hi-tech Solutions, Kitazato Corporation, Fujifilm Irvine Scientific, and Rocket Medical
    Key Market Opportunities Insurance companies covering artificial insemination treatment under medical coverage
    Key Market Drivers Rising infertility issues in people to aid the  market growth

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    [email protected]

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    [email protected]

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    What is the study period of the artificial insemination market report?

    The artificial insemination market forecast period is 2024 - 2032

    What is the artificial insemination Market Growth rate?

    The market is expected to register a CAGR of 8.9% over the next 10 years, according to artificial insemination market research.

    Which region has the highest market growth rate?

    Asia-Pacific is expected to register the highest CAGR during 2024 - 2032

    Which region has the largest share of the market?

    Europe held the largest share in 2021

    What is the expected artificial insemination market size by 2032?

    The market size is expected to be USD 9.2 billion by 2032.

    Who are the key players in the market?

    Vitrolife AB, Genea Limited, Rinovum Women's Health, Pride Angel, Hi-tech Solutions, Kitazato Corporation, Fujifilm Irvine Scientific, and Rocket Medical are the major companies operating in the market.

    1. Executive Summary
    2. Market Introduction
      1. Scope of the Study 14
      2. RESEARCH OBJECTIVE 14
      3. MARKET STRUCTURE 14
      4. ASSUMPTIONS
    3. & LIMITATIONS 15
    4. Research Methodology
      1. DATA MINING 16
      2. SECONDARY RESEARCH 17
      3. PRIMARY RESEARCH 18
      4. BREAKDOWN OF PRIMARY
    5. RESPONDENTS 19
      1. FORECASTING TECHNIQUES 19
      2. Research Methodology
    6. FOR MARKET SIZE ESTIMATION 20
      1. Bottom-up Approach 21
        1. TOP-DOWN
    7. APPROACH 21
      1. DATA TRIANGULATION 22
      2. VALIDATION 22
    8. MARKET
    9. DYNAMICS
      1. OVERVIEW 23
      2. DRIVERS 24
        1. GROWING RATE OF INFERTILITY
    10. IN THE WORLD 24
      1. CHANGING LIFESTYLE AMONG POPULATION 24
        1. RISE
    11. IN NHS FUNDED IN FERTILITY MARKET 24
      1. RESTRAINTS 25
        1. HIGH RISK
    12. OF CONCEIVING TWINS OR TRIPLETS AND OTHER COMPLICATIONS SUCH AS PREMATURE BIRTH
    13. OR MISCARRIAGE 25
      1. OPPORTUNITIES 26
        1. MEDICAL INSURANCE FOR THE
    14. COUPLES OF SAME SEXES 26
    15. MARKET FACTOR ANALYSIS
      1. VALUE CHAIN
    16. ANALYSIS 27
      1. CONSULTING DOCTOR FOR EVALUATION 27
        1. FERTILITY
    17. TESTING OF MALE & FEMALE 28
      1. DIAGNOSIS 28
        1. INSEMNINATION
    18. OF SPERM 28
      1. PORTER’S FIVE FORCES MODEL 29
        1. BARGAINING POWER
    19. OF SUPPLIERS 29
      1. BARGAINING POWER OF BUYERS 29
        1. THREAT OF NEW
    20. ENTRANTS 29
      1. THREAT OF SUBSTITUTES 30
        1. RIVALRY 30
      2. COVID-19
    21. IMPACT ANALYSIS 30
      1. IMPACT ON GROWTH RATE 30
        1. IMPACT ON MAJOR
    22. PLAYERS 30
      1. IMPACT ON MAJOR REGIONS 30
    23. GLOBAL ARTIFICIAL
    24. INSEMINATION MARKET, BY TYPE
      1. OVERVIEW 32
      2. INTRAUTERINE 33
    25. INTRACERVICAL 33
      1. INTRATUBAL 34
    26. GLOBAL ARTIFICIAL INSEMINATION
    27. MARKET, BY END USER
      1. OVERVIEW 35
      2. HOSPITALS & CLINICS 36
      3. FERTILITY CENTRE 36
      4. HOME-BASED 37
    28. GLOBAL ARTIFICIAL
    29. INSEMINATION MARKET, BY REGION
      1. OVERVIEW 38
      2. AMERICAS 39
    30. NORTH AMERICA 40
      1. US 41
        1. CANADA 42
        2. LATIN AMERICA
    31. 43
      1. EUROPE 44
        1. WESTERN EUROPE 45
    32. FRANCE 47
      1. UK 48
        1. ITALY 49
    33. BELGIUM 50
      1. SWEDEN 51
        1. DENMARK 51
        2. EASTERN
    34. EUROPE 54
      1. ASIA-PACIFIC 55
        1. JAPAN 56
        2. CHINA 57
    35. INDIA 58
      1. AUSTRALIA 58
        1. SOUTH KOREA 59
        2. REST OF ASIA-PACIFIC
    36. 60
      1. MIDDLE EAST & AFRICA 61
        1. MIDDLE EAST 62
        2. AFRICA
    37. 63
    38. Competitive Landscape
      1. OVERVIEW 64
      2. COMPETITIVE
    39. BENCHMARKING 65
      1. COMPETITOR DASHBOARD 66
      2. MAJOR GROWTH STRATEGY
    40. IN THE GLOBAL ARTIFICIAL INSEMINATION MARKET 67
      1. THE LEADING PLAYER IN TERMS
    41. OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ARTIFICIAL INSEMINATION MARKET 67
    42. KEY DEVELOPMENT ANALYSIS 68
      1. KEY DEVELOPMENTS & GROWTH STRATEGIES 68
        1. PARTNERSHIPS/COLLABORATIONS/AGREEMENTS 68
        2. EXPANSIONS 68
    43. COMPANY PROFILES
      1. VITROLIFE AB 69
        1. COMPANY OVERVIEW 69
        2. FINANCIAL OVERVIEW 70
        3. PRODUCTS/SERVICES OFFERED 71
    44. KEY DEVELOPMENTS 71
      1. SWOT ANALYSIS 72
        1. KEY STRATEGIES 72
      2. GENEA LIMITED 73
        1. COMPANY OVERVIEW 73
        2. FINANCIAL OVERVIEW
    45. 73
      1. PRODUCTS/SERVICES OFFERED 73
        1. KEY DEVELOPMENTS 73
    46. SWOT ANALYSIS 74
      1. KEY STRATEGIES 74
      2. RINOVUM WOMEN’S HEALTH,
    47. LLC 75
      1. COMPANY OVERVIEW 75
        1. FINANCIAL OVERVIEW 75
    48. PRODUCTS/SERVICES OFFERED 75
      1. KEY DEVELOPMENTS 75
        1. SWOT ANALYSIS
    49. 76
      1. KEY STRATEGIES 76
      2. PRIDE ANGEL 77
        1. COMPANY OVERVIEW
    50. 77
      1. FINANCIAL OVERVIEW 77
        1. PRODUCTS/SERVICES OFFERED 77
        2. KEY DEVELOPMENTS 77
        3. SWOT ANALYSIS 78
        4. KEY STRATEGIES
    51. 78
      1. HI-TECH SOLUTIONS 79
        1. COMPANY OVERVIEW 79
        2. FINANCIAL
    52. OVERVIEW 79
      1. PRODUCTS/SERVICES OFFERED 79
        1. KEY DEVELOPMENTS
    53. 79
      1. SWOT ANALYSIS 80
        1. KEY STRATEGIES 80
      2. KITAZATO
    54. CORPORATION 81
      1. COMPANY OVERVIEW 81
        1. FINANCIAL OVERVIEW 81
        2. PRODUCTS/SERVICES OFFERED 81
        3. KEY DEVELOPMENTS 82
    55. SWOT ANALYSIS 82
      1. KEY STRATEGIES 82
      2. FUJIFILM IRVINE SCIENTIFIC,
    56. INC. 83
      1. COMPANY OVERVIEW 83
        1. FINANCIAL OVERVIEW 83
    57. PRODUCTS/SERVICES OFFERED 84
      1. KEY DEVELOPMENTS 84
        1. SWOT ANALYSIS
    58. 84
      1. KEY STRATEGIES 85
      2. ROCKET MEDICAL 86
        1. COMPANY
    59. OVERVIEW 86
      1. FINANCIAL OVERVIEW 86
        1. PRODUCTS/SERVICES OFFERED
    60. 87
      1. KEY DEVELOPMENTS 87
        1. SWOT ANALYSIS 87
        2. KEY
    61. STRATEGIES 87
    62. APPENDIX
      1. REFERENCES 88
      2. RELATED REPORTS
    63. 89
    64. LIST OF TABLES
    65. TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
    66. 15
    67. TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18
    68. TABLE
    69. GLOBAL ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 32
    70. TABLE 4 GLOBAL ARTIFICIAL INSEMINATION MARKET, FOR INTRAUTERINE, BY REGION, 2022-2030
    71. (USD MILLION) 33
    72. TABLE 5 GLOBAL ARTIFICIAL INSEMINATION MARKET, FOR INTRACERVICAL,
    73. BY REGION, 2022-2030 (USD MILLION) 34
    74. TABLE 6 GLOBAL ARTIFICIAL INSEMINATION
    75. MARKET, FOR INTRATUBAL, BY REGION, 2022-2030 (USD MILLION) 34
    76. TABLE 7 GLOBAL
    77. ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 35
    78. GLOBAL ARTIFICIAL INSEMINATION MARKET, FOR HOSPITALS & CLINICS, BY REGION,
    79. 2030 (USD MILLION) 36
    80. TABLE 9 GLOBAL ARTIFICIAL INSEMINATION MARKET, FOR
    81. FERTILITY CENTRE, BY REGION, 2022-2030 (USD MILLION) 36
    82. TABLE 10 GLOBAL ARTIFICIAL
    83. INSEMINATION MARKET, FOR HOME-BASED, BY REGION, 2022-2030 (USD MILLION) 37
    84. GLOBAL ARTIFICIAL INSEMINATION MARKET, BY REGION, 2022-2030 (USD MILLION) 38
    85. TABLE 12 AMERICAS: ARTIFICIAL INSEMINATION MARKET, BY REGION, 2022-2030 (USD MILLION)
    86. 39
    87. TABLE 13 AMERICAS: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD
    88. MILLION) 40
    89. TABLE 14 AMERICAS: ARTIFICIAL INSEMINATION MARKET, BY END USER,
    90. 2030 (USD MILLION) 40
    91. TABLE 15 NORTH AMERICA: ARTIFICIAL INSEMINATION
    92. MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 41
    93. TABLE 16 NORTH AMERICA: ARTIFICIAL
    94. INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 41
    95. TABLE 17 NORTH AMERICA:
    96. ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 41
    97. US: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 41
    98. US: ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 42
    99. TABLE 20 CANADA: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION)
    100. 42
    101. TABLE 21 CANADA: ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030
    102. (USD MILLION) 42
    103. TABLE 22 LATIN AMERICA: ARTIFICIAL INSEMINATION MARKET, BY
    104. TYPE, 2022-2030 (USD MILLION) 43
    105. TABLE 23 LATIN AMERICA: ARTIFICIAL INSEMINATION
    106. MARKET, BY END USER, 2022-2030 (USD MILLION) 43
    107. TABLE 24 EUROPE: ARTIFICIAL
    108. INSEMINATION MARKET, BY REGION, 2022-2030 (USD MILLION) 44
    109. TABLE 25 EUROPE:
    110. ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 45
    111. TABLE 26
    112. EUROPE: ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 45
    113. TABLE 27 WESTERN EUROPE: ARTIFICIAL INSEMINATION MARKET, BY COUNTRY, 2022-2030
    114. (USD MILLION) 46
    115. TABLE 28 WESTERN EUROPE: ARTIFICIAL INSEMINATION MARKET, BY
    116. TYPE, 2022-2030 (USD MILLION) 46
    117. TABLE 29 WESTERN EUROPE: ARTIFICIAL INSEMINATION
    118. MARKET, BY END USER, 2022-2030 (USD MILLION) 46
    119. TABLE 30 GERMANY: ARTIFICIAL
    120. INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 47
    121. TABLE 31 GERMANY:
    122. ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 47
    123. FRANCE: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 47
    124. TABLE 33 FRANCE: ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION)
    125. 48
    126. TABLE 34 UK: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION)
    127. TABLE 35 UK: ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD
    128. MILLION) 48
    129. TABLE 36 ITALY: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030
    130. (USD MILLION) 49
    131. TABLE 37 ITALY: ARTIFICIAL INSEMINATION MARKET, BY END USER,
    132. 2030 (USD MILLION) 49
    133. TABLE 38 SPAIN: ARTIFICIAL INSEMINATION MARKET,
    134. BY TYPE, 2022-2030 (USD MILLION) 49
    135. TABLE 39 SPAIN: ARTIFICIAL INSEMINATION
    136. MARKET, BY END USER, 2022-2030 (USD MILLION) 50
    137. TABLE 40 BELGIUM: ARTIFICIAL
    138. INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 50
    139. TABLE 41 BELGIUM:
    140. ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 50
    141. SWEDEN: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 51
    142. TABLE 43 SWEDEN: ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION)
    143. 51
    144. TABLE 44 DENMARK: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD
    145. MILLION) 51
    146. TABLE 45 DENMARK: ARTIFICIAL INSEMINATION MARKET, BY END USER,
    147. 2030 (USD MILLION) 52
    148. TABLE 46 FINLAND: ARTIFICIAL INSEMINATION MARKET,
    149. BY TYPE, 2022-2030 (USD MILLION) 52
    150. TABLE 47 FINLAND: ARTIFICIAL INSEMINATION
    151. MARKET, BY END USER, 2022-2030 (USD MILLION) 52
    152. TABLE 48 NORWAY: ARTIFICIAL
    153. INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 53
    154. TABLE 49 NORWAY: ARTIFICIAL
    155. INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 53
    156. TABLE 50 REST
    157. OF WESTERN EUROPE: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION)
    158. 53
    159. TABLE 51 REST OF WESTERN EUROPE: ARTIFICIAL INSEMINATION MARKET, BY END
    160. USER, 2022-2030 (USD MILLION) 54
    161. TABLE 52 EASTERN EUROPE: ARTIFICIAL INSEMINATION
    162. MARKET, BY TYPE, 2022-2030 (USD MILLION) 54
    163. TABLE 53 EASTERN EUROPE: ARTIFICIAL
    164. INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 54
    165. TABLE 54 ASIA-PACIFIC:
    166. ARTIFICIAL INSEMINATION MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 55
    167. ASIA-PACIFIC: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION)
    168. 56
    169. TABLE 56 ASIA-PACIFIC: ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030
    170. (USD MILLION) 56
    171. TABLE 57 JAPAN: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030
    172. TABLE 58 JAPAN: ARTIFICIAL INSEMINATION MARKET, BY END USER,
    173. 2030 (USD MILLION) 57
    174. TABLE 59 CHINA: ARTIFICIAL INSEMINATION MARKET,
    175. BY TYPE, 2022-2030 (USD MILLION) 57
    176. TABLE 60 CHINA: ARTIFICIAL INSEMINATION
    177. MARKET, BY END USER, 2022-2030 (USD MILLION) 57
    178. TABLE 61 INDIA: ARTIFICIAL
    179. INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 58
    180. TABLE 62 INDIA: ARTIFICIAL
    181. INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 58
    182. TABLE 63 AUSTRALIA:
    183. ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 58
    184. TABLE 64
    185. AUSTRALIA: ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION)
    186. 59
    187. TABLE 65 SOUTH KOREA: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030
    188. (USD MILLION) 59
    189. TABLE 66 SOUTH KOREA: ARTIFICIAL INSEMINATION MARKET, BY END
    190. USER, 2022-2030 (USD MILLION) 59
    191. TABLE 67 REST OF ASIA-PACIFIC: ARTIFICIAL
    192. INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION) 60
    193. TABLE 68 REST OF ASIA-PACIFIC:
    194. ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 60
    195. MIDDLE EAST & AFRICA: ARTIFICIAL INSEMINATION MARKET, BY COUNTRY, 2022-2030
    196. (USD MILLION) 61
    197. TABLE 70 MIDDLE EAST & AFRICA: ARTIFICIAL INSEMINATION
    198. MARKET, BY TYPE, 2022-2030 (USD MILLION) 62
    199. TABLE 71 MIDDLE EAST & AFRICA:
    200. ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030 (USD MILLION) 62
    201. MIDDLE EAST: ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022-2030 (USD MILLION)
    202. 62
    203. TABLE 73 MIDDLE EAST: ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022-2030
    204. (USD MILLION) 63
    205. TABLE 74 AFRICA: ARTIFICIAL INSEMINATION MARKET, BY TYPE,
    206. 2030 (USD MILLION) 63
    207. TABLE 75 AFRICA: ARTIFICIAL INSEMINATION MARKET,
    208. BY END USER, 2022-2030 (USD MILLION) 63
    209. TABLE 76 MAJOR MANUFACTURERS IN THE
    210. GLOBAL ARTIFICIAL INSEMINATION MARKET 65
    211. TABLE 77 BENCHMARKING OF MAJOR COMPETITORS
    212. 65
    213. TABLE 78 COMPETITOR DASHBOARD: GLOBAL ARTIFICIAL INSEMINATION MARKET 66
    214. TABLE 79 MOST ACTIVE PLAYER IN THE GLOBAL ARTIFICIAL INSEMINATION MARKET 67
    215. TABLE 80 PARTNERSHIPS/COLLABORATIONS/AGREEMENTS 68
    216. TABLE 81 EXPANSIONS 68
    217. TABLE 82 VITROLIFE AB: PRODUCTS/SERVICES OFFERED 71
    218. TABLE 83 VITROLIFE AB:
    219. TABLE 84 GENEA LIMITED: PRODUCTS/SERVICES OFFERED 73
    220. TABLE 85 RINOVUM WOMEN’S HEALTH, LLC: PRODUCTS/SERVICES OFFERED 75
    221. RINOVUM WOMEN’S HEALTH, LLC: KEY DEVELOPMENTS 75
    222. TABLE 87 PRIDE ANGEL:
    223. PRODUCTS/SERVICES OFFERED 77
    224. TABLE 88 HI-TECH SOLUTIONS: PRODUCTS/SERVICES
    225. OFFERED 79
    226. TABLE 89 KITAZATO CORPORATION: PRODUCTS/SERVICES OFFERED 81
    227. KITAZATO CORPORATION: KEY DEVELOPMENTS 82
    228. TABLE 91 FUJIFILM IRVINE SCIENTIFIC,
    229. INC.: PRODUCTS/SERVICES OFFERED 84
    230. TABLE 92 ROCKET MEDICAL: PRODUCTS/SERVICES
    231. OFFERED 87
    232. LIST OF FIGURES
    233. FIGURE 1 MARKET SYNOPSIS 13
    234. FIGURE
    235. GLOBAL ARTIFICIAL INSEMINATION MARKET 14
    236. FIGURE 3 BOTTOM-UP AND TOP-DOWN
    237. APPROACHES 21
    238. FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL ARTIFICIAL INSEMINATION
    239. MARKET 23
    240. FIGURE 5 DRIVER IMPACT ANALYSIS 25
    241. FIGURE 6 RESTRAINT IMPACT
    242. ANALYSIS 26
    243. FIGURE 7 VALUE CHAIN: GLOBAL ARTIFICIAL INSEMINATION MARKET 27
    244. FIGURE 8 Porter's Five Forces Analysis OF THE GLOBAL ARTIFICIAL INSEMINATION MARKET
    245. 29
    246. FIGURE 9 GLOBAL ARTIFICIAL INSEMINATION MARKET, BY TYPE, 2022 AND 2030 (USD
    247. MILLION) 32
    248. FIGURE 10 GLOBAL ARTIFICIAL INSEMINATION MARKET, BY END USER, 2022
    249. AND 2030 (USD MILLION) 35
    250. FIGURE 11 GLOBAL ARTIFICIAL INSEMINATION MARKET,
    251. BY REGION, 2022 AND 2030 (USD MILLION) 38
    252. FIGURE 12 AMERICAS: ARTIFICIAL INSEMINATION
    253. MARKET, BY REGION, 2022 (%) 39
    254. FIGURE 13 NORTH AMERICA: ARTIFICIAL INSEMINATION
    255. MARKET, BY COUNTRY, 2022 (%) 40
    256. FIGURE 14 EUROPE: ARTIFICIAL INSEMINATION MARKET,
    257. BY REGION, 2022 (%) 44
    258. FIGURE 15 WESTERN EUROPE: ARTIFICIAL INSEMINATION MARKET,
    259. BY COUNTRY, 2022 (%) 45
    260. FIGURE 16 ASIA-PACIFIC: ARTIFICIAL INSEMINATION MARKET,
    261. BY COUNTRY, 2022 (%) 55
    262. FIGURE 17 MIDDLE EAST & AFRICA: ARTIFICIAL INSEMINATION
    263. MARKET, BY COUNTRY, 2022 (%) 61
    264. FIGURE 18 MAJOR STRATEGY ADOPTED BY KEY PLAYERS
    265. FIGURE 19 GLOBAL ARTIFICIAL
    266. INSEMINATION MARKET: Competitive Landscape 68
    267. FIGURE 20 VITROLIFE AB: FINANCIAL
    268. OVERVIEW 70
    269. FIGURE 21 VITROLIFE AB: SWOT ANALYSIS 72
    270. FIGURE 22 GENEA LIMITED:
    271. FIGURE 23 RINOVUM WOMEN’S HEALTH, LLC: SWOT ANALYSIS
    272. FIGURE 24 PRIDE ANGEL: SWOT ANALYSIS 78
    273. FIGURE 25 HI-TECH SOLUTIONS:
    274. SWOT ANALYSIS 80
    275. FIGURE 26 KITAZATO CORPORATION: SWOT ANALYSIS 82
    276. FUJIFILM IRVINE SCIENTIFIC, INC.: FINANCIAL OVERVIEW SNAPSHOT 83
    277. FUJIFILM IRVINE SCIENTIFIC, INC.: SWOT ANALYSIS 84
    278. FIGURE 29 ROCKET MEDICAL:
    279. FINANCIAL OVERVIEW SNAPSHOT 86
    280. FIGURE 30 ROCKET MEDICAL: SWOT ANALYSIS 87

    Artificial Insemination Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027